|
|
|
Phacilitate Limited, The Vier Jahreszeiten Kempinski Hotel, Munich
15-17 October 2007
Visit www.phacilitate.co.uk/leaders for the latest programme information.
|
|
|
|
|
|
Organized by:
|
|
Phacilitate Ltd |
|
Invited Speakers:
|
|
Visit www.phacilitate.co.uk/leaders for the full speaker list which includes:
- Dr Norbert G. Riedel, Corporate Vice President, Chief Scientific Officer, Baxter International Inc
- Dr Bernhard Kirschbaum, Senior Executive Vice President & Member of the Board, Head of Research, Merck Serono
- Irene Norstedt, Deputy Head of Unit, Biotechnology, European Commission
- Dr Emiliangelo Ratti, Senior Vice President & Head, Centre of Excellence for Drug Discovery in Psychiatry, GlaxoSmithKline
- Dr Anthony Ford-Hutchinson, Executive Vice President, Research Medicine, Merck Research Laboratories, Merck & Co, Inc
- Jo Walton, Managing Director & Research Analyst, Healthcare Research, Lehman Brothers
- Joseph B. Bolen, PhD, Chief Scientific Officer, Millennium Pharmaceuticals, Inc
- Kathryn M. Carbone, MD, Associate Director for Research, Center for Biologics Evaluation & Research, FDA
- Dr Douglas Greene, Senior Vice President, Chief Medical Officer, Sanofi-Aventis
- Professor Peter T. Sawicki, Director, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
- Dr Jörg Möller, Senior Vice President, Head, Global Clinical Development, Bayer HealthCare AG, Bayer Schering Pharma Division
- Johan Van Hoof, MD, Senior Vice President & Global Head of Clinical Operations, Johnson & Johnson
- Professor Klaus Nickisch, Senior Vice President, Global Project Management, Bayer Schering Pharma AG
- Dr Paul C. Nakagaki, Head, Pharma Research Strategy, Pharmaceuticals Division, F. Hoffmann-La Roche Ltd
- Dr William M. Kluwe, Global Head of Safety Assessment, Novartis Pharmaceuticals
- Michael Leacock, Director, Pharmaceutical Equity Research, ABN AMRO
- Dr Nicholas Dracopoli, Vice President, Clinical Discovery Technologies, Bristol-Myers Squibb Pharmaceutical Research Institute
- Professor Andrew P. Grieve, Division of Health & Social Care Research, Department of Public Health Sciences, School of Medicine, King's College
- Dr John J. Orloff, Vice President, Development, Novartis Pharmaceuticals Corporation
- Dr Diana Galer, Vice President, Drug Safety Research & Development - Operations, Pfizer Inc
- Dr Susanne Brendler-Schwaab, Head of Project Management Unit, Federal Institute for Drugs & Medical Devices
- Professor Donald R. Stanski, Global Head, Modelling & Simulation, Novartis Pharma AG
- Dr Damian O’Connell, Executive Director & Head of Experimental Medicine, Pfizer Global R&D
- Dr Thomas Senderovitz, Vice President, Global Clinical Pharmacology & Experimental Medicine, UCB Pharma SA.
|
|
|
|
|
|
Deadline for Abstracts:
|
|
n/a
|
|
|
|
|
|
Registration:
|
|
Visit www.phacilitate.co.uk/leaders for information and online registration.
|
|
E-mail:
|
|
nicola@phacilitate.co.uk
|
|
|
|
|
|
|
|